New peanut allergy drug passes first safety check
Disease control
Completed
This study tested a new drug called IGNX001 in 32 adults and older teens with peanut allergy. The main goal was to see if the drug is safe and how the body processes it. Participants received either the drug or a placebo, and researchers monitored for side effects. This is an ear…
Phase: PHASE1 • Sponsor: IgGenix Australia Pty Ltd • Aim: Disease control
Last updated May 01, 2026 16:00 UTC